diabetestalk.net

Tradjenta Compared To Januvia

Linagliptin Versus Sitagliptin In Patients With Type 2 Diabetes Mellitus: A Network Meta-analysis Of Randomized Clinical Trials

Linagliptin Versus Sitagliptin In Patients With Type 2 Diabetes Mellitus: A Network Meta-analysis Of Randomized Clinical Trials

Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials We are experimenting with display styles that make it easier to read articles in PMC. The ePub format uses eBook readers, which have several "ease of reading" features already built in. The ePub format is best viewed in the iBooks reader. You may notice problems with the display of certain parts of an article in other eReaders. Generating an ePub file may take a long time, please be patient. Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials Khosro Keshavarz, Farhad Lotfi, [...], and Shekoufeh Nikfar Diabetes is one of the most common chronic and costly diseases worldwide and type 2 diabetes is the most common type which accounts for about 90% of cases with diabetes. New medication-therapy regimens such as those containing linagliptin alone or in combination with other medications (within the category of DDP-4 inhibitors) must be evaluated in terms of efficacy and compared with other currently used drugs and then enter the medication list of the country. Hence, this study aimed to compare the clinical efficacy of the two drugs, i.e. linagliptin and sitagliptin, in patients with type 2 diabetes. A systematic review was conducted to identify all clinical trials published by 2015 which compared the two drugs in patients with type 2 diabetes. Using keywords such as linagliptin, type 2 diabetes mellitus, sitagliptin and related combinations, we searched databases including Scopus, PubMed, and Web of Science. The quality of the selected studies was evaluated using the Jadad score. Considering primary and secondary outcomes extracted from the reviewed studies, a network meta Continue reading >>

Dpp-4 Inhibitors Januvia, Onglyza, Trajenta, Combiglyze, Janumet, And Jentadueto

Dpp-4 Inhibitors Januvia, Onglyza, Trajenta, Combiglyze, Janumet, And Jentadueto

The image I've chosen for this page is the Roman god, Janus, whose prime characteristic of facing in two directions seems very appropriate for the similarly named drug Januvia, which can be extremely effective and extremely dangerous. Januvia was the first of a family of diabetes drugs that works by increasing the levels of GLP-1 in the bloodstream. Newer drugs in this family include Onglyza and Trajenta, as well as combination drugs which mix the incretin drug in the same pill as metformin. These drugs are Janumet, Kombiglyze, and Jentadueto. GLP-1 is an incretin hormone that stimulates insulin secretion. Another kind of incretin drug, which includes Byetta and Victoza are artificially synthesized molecules that behave just like GLP-1 in the body but last longer. The DPP-4 inhibitors are quite different. They are pills that cause the GLP-1 your body secretes on its own to rise to a higher than normal level by inhibiting the action of DPP-4. DPP-4 is an enzyme (a.k.a. protease) which when it is left to its own devices, chops up GLP-1 and another hormone, GIP. When DPP-4 is inhibited, GLP-1 does not get chopped up and remains active in the body. When GLP-1 is active, it stimulates insulin secretion when blood sugars rise. The Fatal Flaw with These Drugs: They Cause Abnormal Cell Growth and Pre-cancerous Tumors in the Pancreas For several years the FDA has been getting reports that drugs in both families of incretin drugs were causing pancreatitis, a painful inflammation of the pancreas that can destroy large portions of it and lead to full-fledged Type 1 diabetes or even death. They recently decided to study the issue, though, in typical FDA fashion they merely asked for more research without warning doctors to take patients off these dangerous drugs. A study run by a bi Continue reading >>

Januvia Vs Tradjenta

Januvia Vs Tradjenta

Sitagliptin is used with a proper diet and exercise program and possibly with other medications to control high blood sugar. It is used in people with type 2 (non-insulin-dependent) diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Sitagliptin is an anti-diabetic drug that works by increasing levels of natural substances called incretins. Incretins help to control blood sugar by increasing insulin release, especially after a meal. They also decrease the amount of sugar your liver makes. This medication should not be used to treat people with type 1 diabetes (insulin-dependent diabetes). Linagliptin is used with a proper diet and exercise program and possibly with other medications to control high blood sugar. It is used by people with type 2 (non-insulin-dependent) diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Linagliptin is an anti-diabetic drug that works by increasing levels of natural substances called incretins. Incretins help to control blood sugar by increasing insulin release, especially after a meal. They also decrease the amount of sugar your liver makes. This medication should not be used to treat people with type 1 diabetes (insulin-dependent diabetes). my blood sugars have been stabilized at 6.0 for 6 months. I do have to eat every 3-4 hrs or my sugars get low. Allergic. It was helping the three days I was on it and was feeling a bit better but I developed a rash and hives on day 3. Replaced with Glyburide which I Continue reading >>

Tradjenta (linagliptin) Tablets - Why Use Tradjenta?

Tradjenta (linagliptin) Tablets - Why Use Tradjenta?

Eligible patients 18 years or older may pay as little as $10/month with a maximum savings up to $150/monthly prescription. Card valid for 12 consecutive months from activation date. Eligible patients may reenroll for additional 12 consecutivemonth periods by reactivating expired card, benefits not to exceed program expiration on May 31, 2020. If you live in Massachusetts, card expires on the earlier of June 30, 2019, or date AB-rated generic equivalent is available. One card per patient, not transferable, and cannot be combined with any other offer. Program not health insurance. Only valid for commercially insured patients in the 50 United States, DC, and Puerto Rico. Not eligible if prescriptions are paid for in part/full by state or federally funded program(s), like Medicare Part D, Medicaid, Vet. Aff., Dept. of Def., or TRICARE and where prohibited by law. Offer may change at any time, without notice. TRADJENTA is a prescription medicine that is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. TRADJENTA is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine). If you have had inflammation of the pancreas (pancreatitis) in the past, it is not known if you have a higher chance of getting pancreatitis while you take TRADJENTA. What is the most important information I should know about TRADJENTA? Serious side effects can happen to people taking TRADJENTA, including inflammation of the pancreas (pancreatitis), which may be severe and lead to death. Before you start taking TRADJENTA, tell your doctor if you have ever had pancreatitis, gallstones, a history of alcoholism, or high triglyceride levels. Stop taking TRADJENTA and call your doctor right away if you have pain i Continue reading >>

And Along Came Tradjenta Or, The Wacky World Of Type 2 Drugs

And Along Came Tradjenta Or, The Wacky World Of Type 2 Drugs

And Along Came Tradjenta Or, The Wacky World of Type 2 Drugs The world of type 2 diabetes drugs is wacky indeed. While Amylins long-acting version of Byetta called Bydureon and predicted by many experts to become a blockbuster is still held up at FDA, the agency approved a new oral drug earlier this month that is reportedly unremarkable except in the lawsuit it has spurred. The drug is called linagliptin, brand name Tradjenta, a new oral DPP-4 inhibitor from Eli Lilly and Boehringer that can be combined with other BG-lowering meds, especially metformin. Upon its release, Amylin promptly filed a lawsuit against Eli Lilly, its partner in developing Bydureon, accusing Lilly of violating federal laws and engaging in anti-competitive practices because Tradjenta would be a direct competitor for Byetta (exenatide), and Eli Lilly would be able to use the same marketing people on both drugs, giving it the ability to choose which drug is promoted better. Eli Lilly has denied the charges, stating that Tradjenta will not compete with Byetta, therefore the company has committed no crime in allying itself with Boehringer Ingelheim. But then yesterday, a U.S. District Court upheld a restraining order banning Lilly from proceeding with its plans to use the same sales force to sell both drugs. According to David Kliff of Diabetic Investor, an industry-watcher who knows the ins and outs of the Diabetes Pharma World as well as anyone, Tradjenta is basically the same drug as Januvia, with some very slight differences (and) there is no compelling reason for a physician to prescribe Tradjenta over Januvia. He also states that the vast majority of A1C lowering (effect) comes when Januvia is used in combination with metformin; take away the metformin and you have a rather lackluster drug with Continue reading >>

Tradjenta Vs Januvia Uses, Side Effects, Differences

Tradjenta Vs Januvia Uses, Side Effects, Differences

Brexpiprazole vs Aripiprazole - Which Is The Best Antipsychotic for Schizophrenia? Tradjenta is a prescription drug used to treat type 2 diabetes mellitus in adults. It belongs to a group of drugs called dipeptidyl peptidase-4 inhibitors, that help lower blood sugar levels. The usual recommended dose is 5 mg once a day. Because of the way this medication works, it is likely to cause low blood sugar levels, compared with some other type 2 diabetes drugs. another drug which is a DPP-4 inhibitor that helps lower the blood sugar levels. The usual dose is 100 mg orally once per day. In conclusion, both these medicines areDPP-4 inhibitors but have different main active ingredients. Both have to be taken once per day but in a different quantity. Both have plenty of side effects and dont cure diabetes mellitus. According to a 2005 study issued in the journal Phytomedicine, garlic considerably decreased total cholesterol,serum glucose, and triglycerides. Reduce your intake of omega 6 fatty acids (all oils with the exception of olive, fish, and flax oil are omega 6) and increase omega-3 fats.Healthy sources of omega 3 essential fatty acids include flaxseeds (the best source), chia seeds, walnuts, almonds, broccoli, cabbage, and hazelnuts. Research shows that this spice has a positive effect on the glycemic control in sufferers with diabetes mellitus. Moderate physical exercise stimulates GLUT4 transporter (the insulin-regulated glucosetransporter) that signals cells to open and receive energy, allowing sugar to enter the cells. Chromium is a trace mineral which is involved in lipid and carbohydrate metabolism. Foods rich in chromium can improve the glucose tolerance factor in the body. They include broccoli, sweet potatoes, oats, grapes, bananas, garlic, lettuce, black pepper, r Continue reading >>

Compare Tradjenta Vs Januvia - Iodine.com

Compare Tradjenta Vs Januvia - Iodine.com

Head-to-head comparisons of medication uses, side effects, ratings, and more. Tradjenta (linagliptin) is good add-on medicine for controlling your blood sugar, but may cause body aches. Januvia (sitagliptin) is a good add-on treatment if your blood sugars are not controlled and you don't want to use an injectable medicine. 3.2/ 5 average rating with 143 reviewsforJanuvia Good add-on medicine if your blood sugars are still not controlled Good option if you have bad liver or kidney function. Does not cause hypoglycemia (low blood sugar) when taken by itself. Januvia (sitagliptin) is not linked to worsening heart failure like other medicines in its class. Uses the hormones naturally produced by your body to affect how sugar is processed. It is less likely to cause weight gain and low blood sugar compared to other diabetes medicines. Not first-choice anti-diabetes medicine because it doesn't lower blood sugar levels as much as others. Available as brand only and may be expensive Lowers A1c (average blood sugar over time) by less than 1%. Some people might get frequent cold-like symptoms. Rare but serious side effects include pancreatitis and severe joint pain. Continue reading >>

Efficacy And Safety Of Vildagliptin, Sitagliptin, And Linagliptin As Add-on Therapy In Chinese Patients With T2dm Inadequately Controlled With Dual Combination Of Insulin And Traditional Oral Hypoglycemic Agent

Efficacy And Safety Of Vildagliptin, Sitagliptin, And Linagliptin As Add-on Therapy In Chinese Patients With T2dm Inadequately Controlled With Dual Combination Of Insulin And Traditional Oral Hypoglycemic Agent

Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent We aimed to evaluate the efficacy and safety of the three dipeptidyl peptidase 4 (DPP-4) inhibitors (vildagliptin, sitagliptin, and linagliptin) as add-on therapy in Chinese patients with type 2 diabetes mellitus (T2DM)inadequately controlled on dual combination of insulin and metformin or acarbose. A total of 535 T2DM patients who failed to achieve glycemic control with insulin and a traditional oral hypoglycemic agent were randomized to receive vildagliptin, sitagliptin, or linagliptin. Body mass index, glycosylated hemoglobin (HbA1c), fasting and postprandial plasma glucose (FPG and PPG), insulin dose, and adverse events were evaluated during the study. The baseline HbA1c was 9.591.84% (vildagliptin group), 9.221.60% (sitagliptin group), and 9.581.80% (linagliptin group). At week 12 it was 8.161.29% (vildagliptin), 8.561.96% (linagliptin), and 8.261.10% (sitagliptin). The changes in HbA1c from baseline were 1.330.11% (vildagliptin), 0.840.08% (sitagliptin) and 0.810.08% (linagliptin), the vildagliptin group had the greatest reduction in HbA1c (P<0.05). The proportions of patients that reached target HbA1c were 66.27% (vildagliptin), 52.73% (sitagliptin), and 55.49% (linagliptin), the vildagliptin group had the highest one (P<0.05). The baseline FPG and PPG values in the three groups were at the same level. At week 12, mean FPG levels in the vildagliptin (7.311.50mmol/L) and linagliptin (6.901.55mmol/L) groups were significantly lower than in the sitagliptin group (8.024.48mmol/L; P<0.05); the linagliptin group had the lowest mean PPG followed by the vildaglip Continue reading >>

New Diabetes Medications Cost 100 Times More Than Established Treatments

New Diabetes Medications Cost 100 Times More Than Established Treatments

“New is not always better.” This caution seems reasonable when considering the value of the recently approved medications for treatment of Type 2 (adult type) diabetes. These drugs include three new classes of medication referred to as GLP-1 analogs, DPP-4 inhibitors and most recently SGLT-2 inhibitors. The focus of this discussion will be the most widely prescribed of the newcomers, the DPP-4 inhibitors. The first thing consumers will notice about the new diabetes medications are their TV commercial friendly names, Januvia, Onglyza, Tradjenta, and Nesina. Mix these newcomer drugs together into a single pill with the venerable low cost generic metformin and the names becomes Janumet, Kombiglyze, Jentadueto, and Kazano. The next thing a consumer will notice is the price tag. At the local pharmacy in Jupiter, Florida the retail prices of a 3 month supply of Januvia, Onglyza or Tradjenta are all about $1100. A three month supply of the established generic drug, glipizide, is $9.99 and metformin is between zero and $41. The new drugs are being heavily promoted by the biggest names in the pharmaceutical industry directly to consumers and to doctors. Merck, Bristol-Myers Squibb, Lilly, AstraZeneca, Boehringer Ingelheim and Takeda are behind the ad campaigns. The success of these promotions has been impressive with the percentage of diabetics receiving treatment with the new drugs rising rapidly. Data Monitor, a company tracking pharmaceutical trends reported in 2014 that DPP4 drugs now dominate the diabetes care market with 40% of sales in dollars, (with Januvia leading the pack. The rapid expansion of this class of diabetes medication should be an indication of their great advantage over the established generic drugs such as metformin and sulfonylureas (predominantly gli Continue reading >>

Dpp-4 Inhibitors - Dipeptidyl Peptidase-4 Inhibitor - Gliptins

Dpp-4 Inhibitors - Dipeptidyl Peptidase-4 Inhibitor - Gliptins

The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Products alogliptin -NESINA® Linagliptin - Tradjenta™ Saxagliptin - Onglyza™ Sitagliptin - Januvia® Combination Products JANUMET® (sitagliptin and metformin HCl) tablets JANUMET ® XR (sitagliptin and metformin HCl extended-release) JENTADUETO® XR (linagliptin and metformin hydrochloride ER) KOMBIGLYZE XR (saxagliptin and metformin HCl ER) OSENI® (alogliptin and pioglitazone) --® Typical reductions in A1C values - DPP-4 INHIBITORS: ~ 0.74% (0.73 - 1.2) Background Overview Secretagogues Insulin sensitizers Alpha-glucosidase inh Peptide analogs INDICATIONS AND USAGE NESINA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. DOSAGE AND ADMINISTRATION •The recommended dose in patients with normal renal function or mild renal impairment is 25 mg once daily. •Can be taken with or without food. •Adjust dose if moderate or severe renal impairment or end-stage renal disease (ESRD). DOSAGE FORMS AND STRENGTHS Tablets: 25 mg, 12.5 mg and 6.25 mg CONTRAINDICATIONS History of a serious hypersensitiv Continue reading >>

Januvia And Tradjenta Battle For Dpp-4 Supremacy

Januvia And Tradjenta Battle For Dpp-4 Supremacy

Valentina Gburcik, cardiovascular & metabolic disorders analyst, GlobalData Enrique Conterno, SVP and president, Lilly Diabetes Januvia is facing increased competition in a market space that seems to be getting evermore crowded. The DPP-4 inhibitor from Merck, which was first to market for the treatment of type 2 diabetes, racked up sales of $4 billion in 2012. However, recently released results for the third quarter of 2013 revealed an unexpectedly poor performance for the medicine. The results are being blamed on increased competition in the market, primarily from another Big Pharma titan. Valentina Gburcik, cardiovascular & metabolic disorders analyst for research and consulting firm GlobalData, notes the competition in this space is stronger than ever, with Big Pharma firms launching new therapies into this market with a force designed to sweep away existing medicines, as well as competitors. “As most therapies within one drug class hardly differentiate from each other, and the differences between entire classes are also relatively unimpressive, business strategy behind new products now means more than anything,” notes Gburcik. Much of the increased competition for Januvia is coming from Eli Lilly and Company. The company’s Tradjenta product, the third-to-market DPP-4 inhibitor, continues to perform very strongly in the market, according to Gburcik. “Eli Lilly and BI (Boehringer Ingelheim) have been adopting a different strategy from Merck by working on diversification of the diabetes portfolio, and they will soon market treatments covering every single anti-diabetes drug class,” says Gburcik. “Instead of focusing on brand, Eli Lilly focuses on the most comprehensive coverage of patients’ needs, and this is certainly strengthening its relationship with Continue reading >>

Compare Januvia Vs Tradjenta - Comprehensive Analysis By Treato

Compare Januvia Vs Tradjenta - Comprehensive Analysis By Treato

Diabetes Cancer COPD Alzheimer's Hepatitis C Treato does not review third-party posts for accuracy of any kind, including for medical diagnosis or treatments, or events in general. Treato does not provide medical advice, diagnosis or treatment. Usage of the website does not substitute professional medical advice. The side effects featured here are based on those most frequently appearing in user posts on the Internet. The manufacturer's product labeling should always be consulted for a list of side effects most frequently appearing in patients during clinical studies. Talk to your doctor about which medications may be most appropriate for you. The information reflected here is dependent upon the correct functioning of our algorithm. From time-to-time, our system might experience bugs or glitches that affect the accuracy or correct application of mathematical algorithms. We will do our best to update the site if we are made aware of any malfunctioning or misapplication of these algorithms. We cannot guarantee results and occasional interruptions in updating may occur. Please continue to check the site for updated information. Continue reading >>

Tradjenta Side Effects Center

Tradjenta Side Effects Center

Tradjenta (linagliptin) tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Common side effects of Tradjenta include cough, weight gain, muscle or joint pain, headache, low blood sugar. Tradjenta may cause serious side effects, including: inflammation of the pancreas (pancreatitis, symptoms include severe pain in your upper stomach spreading to your back, nausea and vomiting, loss of appetite, fast heart rate), fever, and headache with a severe blistering, peeling, and red skin rash. The recommended dose of Tradjenta is 5 mg once daily. Tradjenta may interact with bosentan, dexamethasone, ketoconazole, quinidine, verapamil, rifabutin, rifampin, rifapentine, St. John's wort, phenobarbital and other barbiturates, medication to treat HIV or AIDS, medicines to treat narcolepsy, medicines used to prevent organ transplant rejection, seizure medications, probenecid, nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin or other salicylates (including Pepto-Bismol), sulfa drugs, monoamine oxidase inhibitors (MAOIs), beta-blockers, or other oral diabetes medications. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Tradjenta; it is not expected to harm an unborn baby. It is unknown if Tradjenta passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding. Our Tradjenta (linagliptin) Tablets Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to Continue reading >>

Similarities & Differences Between Tradjenta Vs Januvia

Similarities & Differences Between Tradjenta Vs Januvia

Tradjenta, the brand name of Linagliptin, is an oral diabetes drug that is prescribed to patients with type 2 diabetes. This medication works by regulating the amount of insulin the pancreas produces after eating a meal. Linagliptin can be used alone or in combination with other diabetes drugs to reduce high blood glucose levels in people with type 2 diabetes. The drug used together with exercise, diet, weight control and blood glucose testing. You should not change any of these factors in order to avoid affecting your blood glucose levels. Januvia is the brand name of Sitagliptin , and is used to treat patients with type 2 diabetes. It can be used together with other diabetes drugs, but should not be used to treat type 1 diabetes . This medication is supposed to be taken orally, and can be taken with or without food. Your dosage will vary depending on how you respond to treatment, your medical condition, and kidney function. You should not take this medication if you are in a state of diabetic ketoacidosis or you are allergic to Sitagliptin. Similarities and Differences Between Tradjenta vs Januvia Both Tradjenta and Januvia are oral medications that are used together with an exercise and diet program to control high blood glucose in patients with type 2 diabetes.The medications can be prescribed to patients with type 2 diabetes to help them control their blood glucose levels. Thus, reducing the risk of long-term health problems. However,these medications should not be used to treat patients who are under the age of 18. Bothdrugs belongs to a class of medications known as DPP-4 inhibitors . DPP-4 inhibitors are responsible for blocking the action of an enzyme called DPP-4 that destroys incretins, which reduces blood sugar levels. This helps to reduce high levels of bl Continue reading >>

Dpp-iv Inhibitors

Dpp-iv Inhibitors

Inhibits the degradation of incretins such as GLP-1 by inhibiting the enzyme dipeptidyl peptidase IV (DPP-IV). The incretin effect is prolonged, enhancing glycemic control through various mechanisms, primarily by stimulating insulin synthesis and secretion in a glucose-dependant manner and by reducing glucagon secretion. brand name preparation manufacturer route form dosage^ cost* Januvia sitagliptin phosphate Merck oral tablet 25 mg $885 for 90 tabs oral tablet 50 mg $885 for 90 tabs oral tablet 100 mg $295 for 30 tabs Onglyza saxagliptin Bristol-Myers Squibb oral tablet 2.5 mg $295 for 30 tabs oral tablet 5 mg $885 for 90 tabs Tradjenta linagliptin Eli Lilly oral tablet 5 mg $870 for 90 tabs Janumet sitagliptin phosphate + metformin hydrochloride Merck Sharp & Dohme Corp. oral tablet 50/500 mg $885 for 180 tabs oral tablet 50/1000 mg $885 for 180 tabs Nesina alogliptin Takeda oral tablet 6.25 mg $374 for 30 tabs oral tablet 12.5 mg $374 for 30 tabs oral tablet 25 mg $374 for 30 tabs **Patient Assistant Programs: ** Information gathered by Heather Tran and Gladimir Elysee *Prices represent cost per unit specified, are representative of "Average Wholesale Price" (AWP). ^Dosage is indicated in mg unless otherwise noted. Continue reading >>

More in diabetes